Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Regeneron Pharmaceuticals Inc (REGN)  
$962.49 3.81 (0.39%) as of 4:30 Thu 3/28


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 104,690,000
Market Cap: 100.76(B)
Last Volume: 461,806 Avg Vol: 778,943
52 Week Range: $692.45 - $993.35
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:

    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  150
Guru Rank Value     : 6.9
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 63,057 86,630 125,378 345,405
Total Sell Value $59,114,723 $78,626,388 $110,854,479 $264,225,777
Total People Sold 12 13 15 19
Total Sell Transactions 25 38 56 131
End Date 2023-12-28 2023-09-26 2023-03-28 2022-03-28

   
Records found: 1366
  Page 1 of 55  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Murphy Andrew J EVP Research   •       –      –    2024-03-14 4 AS $951.92 $5,531,290 D/D (5,783) 48,306 1%     
   Murphy Andrew J EVP Research   •       –      –    2024-03-13 4 D $971.82 $13,816,365 D/D (14,217) 54,089     -
   Murphy Andrew J EVP Research   •       –      –    2024-03-13 4 OE $399.66 $7,993,200 D/D 20,000 68,306     -
   Mccourt Marion EVP Commercial   •       –      –    2024-03-01 4 AS $967.50 $346,365 D/D (358) 13,431 -2%     
   Ryan Arthur F Director   –       •      –    2024-03-01 4 AS $967.50 $98,205 D/D (100) 18,282 -2%     
   Sing George L Director   –       •      –    2024-02-26 4 S $990.00 $992,500 D/D (1,000) 26,349 2%     
   Sing George L Director   –       •      –    2024-02-26 4 OE $413.33 $413,330 D/D 1,000 26,849     -
   Stahl Neil EVP Research and Development   •       –      –    2024-02-26 4 GD $0.00 $0 D/D 1,020 50,999     -
   Larosa Joseph J EVP General Counsel and Secret   •       –      –    2024-02-26 4 S $990.00 $990,000 D/D (1,000) 36,543 2%     
   Bassler Bonnie L Director   –       •      –    2024-02-26 4 S $979.25 $836,280 D/D (854) 1,382 2%     
   Bassler Bonnie L Director   –       •      –    2024-02-26 4 OE $391.92 $334,700 D/D 854 2,236     -
   Sing George L Director   –       •      –    2024-02-23 4 S $985.00 $492,500 D/D (500) 26,349 2%     
   Sing George L Director   –       •      –    2024-02-23 4 OE $413.33 $206,665 D/D 500 26,849     -
   Sing George L Director   –       •      –    2024-02-22 4 S $960.00 $2,895,000 D/D (3,000) 26,349 -0%     
   Sing George L Director   –       •      –    2024-02-22 4 OE $413.33 $1,239,990 D/D 3,000 27,349     -
   Larosa Joseph J EVP General Counsel and Secret   •       –      –    2024-02-22 4 S $967.65 $967,650 D/D (1,000) 37,543 -0%     
   Yancopoulos George Bd. Co-Chair, President & CSO   •       •      –    2024-02-15 4 D $953.83 $117,894,342 D/D (123,601) 801,608     -
   Yancopoulos George Bd. Co-Chair, President & CSO   •       •      –    2024-02-15 4 OE $399.66 $69,030,474 D/D 172,723 925,209     -
   Van Plew Daniel P EVP & General Mgr, Industrial   •       –      –    2024-02-14 4 S $937.94 $9,831,727 D/D (10,434) 20,378 -2%     
   Van Plew Daniel P EVP & General Mgr, Industrial   •       –      –    2024-02-09 4 D $951.68 $23,735,851 D/D (24,941) 30,812     -
   Van Plew Daniel P EVP & General Mgr, Industrial   •       –      –    2024-02-09 4 OE $372.46 $13,382,510 D/D 35,375 47,153     -
   Fenimore Christopher R. SVP Finance & CFO   •       –      –    2024-02-09 4 S $950.49 $4,689,320 D/D (4,919) 14,372 -1%     
   Sing George L Director   –       •      –    2024-02-09 4 S $955.00 $477,500 D/D (500) 26,349 -1%     
   Sing George L Director   –       •      –    2024-02-09 4 OE $413.33 $206,665 D/D 500 26,849     -
   Sing George L Director   –       •      –    2024-02-08 4 S $945.00 $472,500 D/D (500) 26,349 -2%     

  1366 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 55
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed